C07K 14/4735
Villin
Official title: {Villin}
C07K14/4735 (Villin) appears on 10 US grants and 4 published applications in this corpus.
Search patents in C07K- Granted patents
- 10
- Published applications
- 4
- Assignees
- 10
- Inventors
- 26
- Latest grant
- 19 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 2 | 0 |
| 1998 | 3 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 1 |
| 2003 | 1 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 1 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 0 |
| 2021 | 0 | 1 |
| 2022 | 0 | 0 |
| 2023 | 0 | 0 |
| 2024 | 0 | 2 |
| 2025 | 0 | 0 |
| 2026 | 1 | 0 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Ezrin peptide 1 for use in a method of treating COVID-1919 May 2026US 12,629,405 B2Pantapharm AG
- Regulatory sequences of the mouse villin gene—use in transgenesis27 Jun 2006US 7,067,648 B2Centre National De La Recherche Scientifique
- I-Sce I induced gene replacement and gene conversion in embryonic stem cells20 May 2003US 6,566,579 B1Centre Nationale de la Recherche Scientifique
- Actin-binding polypeptides and nucleic acids encoding the same16 Nov 1999US 5,985,608 AUniversity of Massachusetts
- Polyphoshoinositide binding peptides for intracellular drug delivery8 Dec 1998US 5,846,743 AThe Brigham and Women S Hospital, Inc.
- Ezrin peptide 1 for use in a method of treating covid-1911 Jul 2024US 2024/0226231 A1Pantapharm AG
- Ezrin peptide 1 for use in a method of treating post covid-196 Jun 2024US 2024/0180999 A1
- Methods of modulating m2 macrophage polarization and use of same in therapy17 Jun 2021US 2021/0177895 A1Yeda Research and Development Co. Ltd.
- Regulatory sequences of the mouse villin gene - use in transgenesis1 Aug 2002US 2002/0102705 A1Centre National De La Recherche Scientifique
Most cited
By later US patents
- Polyphoshoinositide binding peptides for intracellular drug delivery58US 5,846,743 AThe Brigham and Women S Hospital, Inc. · 1998
- I-Sce I induced gene replacement and gene conversion in embryonic stem cells40US 6,566,579 B1Centre Nationale de la Recherche Scientifique · 2003
- I Sce I-induced gene replacement and gene conversion in embryonic stem cells34US 5,830,729 ACentre National De La Recherche Scientifique · 1998
- Polyphosphoinsitide binding peptides for intracellular drug delivery13US 5,783,662 AThe Brigham and Women S Hospital, Inc. · 1998
- Agents for the in vitro diagnosis of malignant cells originating in the digestive tract4US 5,188,967 ACentre National De La Recherche Scientifique · 1993